Clinical Trial Finder

I

Inclusion Criteria:

• - A subject will be eligible for inclusion in the study only if all of the following criteria are met: 1.

All patients must be willing to and have the capacity to give written informed consent and have signed and dated the informed consent form in accordance with ICH and GCP guidelines. 2. All patients must be able to speak and understand English proficiently. 3. Histologically or cytologically confirmed diagnosis of a solid tumor malignancy within the past 5 years. a. If the original histologic proof of malignancy is > 5 years, then pathological (i.e., more recent) confirmation is required (e.g., from a systemic metastasis or brain metastasis) 4. Brain metastases must be visible on contrast-enhanced MRI. a. Patients who had undergone radiosurgery or surgical resection and are planning adjuvant HA-WBRT do not have to have visible disease but do need a baseline MRI. 5. Karnofsky performance status 70-100% 6. Serum creatinine ≤ 3 mg/dL and creatinine clearance ≥ 30 mL/min as determined by Cockcroft-Gault. 7. Negative urine pregnancy test within 14 days of Day 1 for Women of Childbearing Potential. 8. Women of childbearing potential and men with female partners of childbearing potential must have no plans for further conception and must practice adequate contraception.

Exclusion Criteria:

• - A subject will not be eligible for inclusion in the study if any of the following criteria are met: 1.

Subject is lactating or is pregnant. 2. Severe, active co-morbidity, defined as follows: 1. Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months. 2. Transmural myocardial infarction within the last 6 months. 3. Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration. 4. Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration. 5. Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects. 3. Intractable seizures while on adequate anticonvulsant therapy (i.e., more than one seizure per month for the past 2 months) 4. Clinically significant abnormalities in screening laboratory tests that would affect patient safety as determined by the principal investigator. 5. History of psychiatric disorder requiring ongoing medical management. 6. History of substance abuse including alcohol within past 5 years. Appropriately prescribed medication for the treatment of pain or other symptoms related to the underlying malignancy is acceptable. 7. Chronic kidney disease defined as the presence of significant proteinuria on urinalysis and/or eGFR of <60mL/min, as calculated by the clinical site laboratory. 8. Inability to follow the instructions or an unwillingness to cooperate with study procedures. 9. Known allergy to any component of MW151 or placebo as described in investigator's brochure. 10. Received treatment with and/or planned treatment with systemic chemotherapy within 3 days prior, during, or for at least 3 days after completion of HA-WBRT. Concurrent immunotherapy is permitted. 11. Prior whole-brain radiotherapy. 12. Use of chronic short-acting benzodiazepine. 13. Use of NSAIDS or steroids within 3 days prior to dosing. 14. Any reason or opinion of the investigator that would prevent the subject from participation in the study

In Part A, 10 subjects will receive MW151 in an open label evaluation. At least 5 of these subjects will be male. For each subject, safety and tolerability data for the first 24 hours will be reviewed prior to the continuation of dosing. Subjects will also be evaluated for safety during week 1, during week 2, and at week 4. Once the data from Part A have been reviewed by the Safety Monitoring Committee (SMC), an additional 30 subjects will be recruited to Part B. These subjects will be randomly assigned to MW151 or placebo in a 1:1 ratio. In both parts A and B subjects will take study drug (males), or the first daily dose of study drug (females) before HA-WBRT which will be administered once a day (3Gy), five days a week (Monday to Friday) for two weeks, for total of ten treatments and 30 Gy.

Arms

Experimental: Part A: Open Label

10 subjects will receive MW151 in an open label evaluation.

Experimental: Part B: Randomized, placebo-controlled

30 subjects will be randomly assigned to MW151 or placebo in a 1:1 ratio.

Interventions

Drug: - MW151

Females: 20 mg MW151 daily (10 mg capsule BID), for 28 days; Males: 10 mg MW151 daily (10 mg capsule QD), for 28 days.